Browse by author
Lookup NU author(s): Dr Margaret Piggott, Dr Heather Dickinson, Professor Ian McKeith, Emeritus Professor Robert Perry, Emeritus Professor Elaine Perry
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Dementia with Lewy bodies (DLB) is characterized by progressive dementia with two of three core symptoms; Parkinsonism, visual hallucinations or disturbances of consciousness/fluctuating attention. Dementia in Parkinson's disease (PDD) has similar neuropsychiatric characteristics. Reduced nigrothalamic dopamine and altered thalamic D2 receptors may mediate some of the non-motor symptoms of DLB and PDD. The study aims were to ascertain whether thalamic D2 density was altered in Parkinson's disease (PD), PDD and DLB, and whether D2 density was related to core symptoms. Thalamic D2 receptor binding was measured by post-mortem autoradiography in 18 cases of DLB, 13 PDD, 6 PD and 14 normal elderly controls. Highest D2 density in control cases was in the intralaminar, midline, anterior and mediodorsal nuclei. In PD without dementia D2 binding was elevated above controls in all thalamic regions, significantly in reticular, laterodorsal, centromedian, ventral centromedian, parafascicular, paraventricular, ventroposterior, ventrolateral posterior, and ventrointermedius nuclei. Compared to controls, DLB cases with Parkinsonism (DLB+EPS) had significantly elevated D2 receptor density in laterodorsal and ventrointermedius nuclei; PDD cases had significantly raised density in the ventrointermedius, and DLB cases without Parkinsonism (DLB-EPS) did not show increased D2 density in any areas. In DLB and PDD cases with disturbances of consciousness, cases treated with neuroleptics had higher D 2 binding in all thalamic regions, significantly in the mediodorsal and ventrolateral posterior nuclei. D2 receptor binding did not vary with cognitive decline (MMSE) or visual hallucinations, but was significantly higher with increased extrapyramidal symptoms. © 2006 Collegium Internationale Neuropsychopharmacologicum.
Author(s): Piggott MA, Ballard CG, Dickinson HO, McKeith IG, Perry RH, Perry EK
Publication type: Article
Publication status: Published
Journal: International Journal of Neuropsychopharmacology
Year: 2007
Volume: 10
Issue: 2
Pages: 231-244
Print publication date: 01/04/2007
ISSN (print): 1461-1457
ISSN (electronic): 1469-5111
Publisher: Cambridge University Press
URL: http://dx.doi.org/10.1017/S146114570600647X
DOI: 10.1017/S146114570600647X
PubMed id: 16448581
Altmetrics provided by Altmetric
